Par acquires Teva's divested ANDAs, and is already shipping fentanyl citrate
This article was originally published in Scrip
Executive Summary
Par Pharmaceutical has sealed the deal on acquiring rights to three products from Teva Pharmaceutical Industries, which the Israeli firm was required by the US Federal Trade Commission to divest before it could acquire US biotech Cephalon for $6.8 billion (scripintelligence.com, 11 October 2011).